Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:41 AM
Ignite Modification Date:
2025-12-25 @ 4:41 AM
NCT ID:
NCT02543918
Eligibility Criteria:
Inclusion Criteria:
* Healthy males and females without compromised immune system
* Have a body mass Index of 18 to 32 kilograms per square meter (kg/m²)
Exclusion Criteria:
* Previously completed or withdrawn from an ixekizumab study or a study investigating interleukin-17 (IL-17) antagonists
* Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
* Have known allergy or hypersensitivity to any biologic therapy
* Past vaccination allergy or Arthus-type hypersensitivity
* Received a tetanus toxoid-containing vaccine within the last 5 years
* Severe allergic reaction to Boostrix
* Allergic to latex
* Have been immunized with pneumococcal vaccine
* Known hypogammaglobulinemia
* History of Guillain-Barre Syndrome
* Active infectious disease
* Had a live vaccination within 1 year prior to screening, or intend to have a live vaccination during the course of the study
* Evidence of a significant uncontrolled neuropsychiatric disorder -
* Have a score of 3 on Item 12 of the Quick Inventory of Depressive Symptomatology-Self Report (16 Items) at screening
* Evidence of Human Immunodeficiency Virus infection, Hepatitis C, B
* Had symptomatic herpes zoster within 3 months of screening
* Women who are lactating
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT02543918
Study Brief:
Protocol Section:
NCT02543918